TransCode Therapeutics has appointed Dr. Phillip D. Zamore to its Scientific Advisory Board, a strategic move that could significantly enhance the company's RNA-targeted cancer therapy research. Dr. Zamore, a renowned expert in RNA interference (RNAi) and co-founder of Alnylam Pharmaceuticals, brings extensive expertise in RNA biology and gene silencing mechanisms.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Zamore's election to the National Academy of Sciences underscores his significant contributions to the field. His addition to TransCode's advisory board signals a potential acceleration in the company's innovative approach to treating metastatic cancers.
TransCode's lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis. With Zamore's expertise, the company may be better positioned to develop advanced RNA therapeutic strategies that could potentially transform cancer treatment approaches.
The appointment highlights the ongoing evolution of RNA-based therapeutics and their increasing importance in targeting complex genetic mechanisms underlying diseases like cancer. Zamore's involvement could provide critical insights into improving RNA delivery technologies and identifying novel genetic targets for treatment.
